216 related articles for article (PubMed ID: 14667218)
1. Optimization of the pharmacophore model for 5-HT7R antagonism. Design and synthesis of new naphtholactam and naphthosultam derivatives.
López-Rodríguez ML; Porras E; Morcillo MJ; Benhamú B; Soto LJ; Lavandera JL; Ramos JA; Olivella M; Campillo M; Pardo L
J Med Chem; 2003 Dec; 46(26):5638-50. PubMed ID: 14667218
[TBL] [Abstract][Full Text] [Related]
2. A three-dimensional pharmacophore model for 5-hydroxytryptamine6 (5-HT6) receptor antagonists.
López-Rodríguez ML; Benhamú B; de la Fuente T; Sanz A; Pardo L; Campillo M
J Med Chem; 2005 Jun; 48(13):4216-9. PubMed ID: 15974573
[TBL] [Abstract][Full Text] [Related]
3. Benzimidazole derivatives. 3. 3D-QSAR/CoMFA model and computational simulation for the recognition of 5-HT(4) receptor antagonists.
López-Rodríguez ML; Murcia M; Benhamú B; Viso A; Campillo M; Pardo L
J Med Chem; 2002 Oct; 45(22):4806-15. PubMed ID: 12383006
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of new serotonin 5-HT7 receptor ligands. Determinants of 5-HT7/5-HT1A receptor selectivity.
Medina RA; Sallander J; Benhamú B; Porras E; Campillo M; Pardo L; López-Rodríguez ML
J Med Chem; 2009 Apr; 52(8):2384-92. PubMed ID: 19326916
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of benzoisothiazole derivatives possessing N,N-dimethylformimidamide group as 5-HT₆ receptor antagonists.
Yoo E; Hayat F; Rhim H; Park Choo HY
Bioorg Med Chem; 2012 Apr; 20(8):2707-12. PubMed ID: 22405919
[TBL] [Abstract][Full Text] [Related]
6. Benzimidazole derivatives as new serotonin 5-HT6 receptor antagonists. Molecular mechanisms of receptor inactivation.
de la Fuente T; Martín-Fontecha M; Sallander J; Benhamú B; Campillo M; Medina RA; Pellissier LP; Claeysen S; Dumuis A; Pardo L; López-Rodríguez ML
J Med Chem; 2010 Feb; 53(3):1357-69. PubMed ID: 20078106
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and structure-activity relationships of a new model of arylpiperazines. Study of the 5-HT(1a)/alpha(1)-adrenergic receptor affinity by classical hansch analysis, artificial neural networks, and computational simulation of ligand recognition.
López-Rodríguez ML; Morcillo MJ; Fernández E; Rosado ML; Pardo L; Schaper K
J Med Chem; 2001 Jan; 44(2):198-207. PubMed ID: 11170629
[TBL] [Abstract][Full Text] [Related]
8. Medicinal chemistry driven approaches toward novel and selective serotonin 5-HT6 receptor ligands.
Holenz J; Mercè R; Díaz JL; Guitart X; Codony X; Dordal A; Romero G; Torrens A; Mas J; Andaluz B; Hernández S; Monroy X; Sánchez E; Hernández E; Pérez R; Cubí R; Sanfeliu O; Buschmann H
J Med Chem; 2005 Mar; 48(6):1781-95. PubMed ID: 15771424
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and structure-activity relationships of a new model of arylpiperazines. 5. Study of the physicochemical influence of the pharmacophore on 5-HT(1a)/alpha(1)-adrenergic receptor affinity: synthesis of a new derivative with mixed 5-HT(1a)/d(2) antagonist properties.
López-Rodríguez ML; Morcillo MJ; Fernández E; Porras E; Orensanz L; Beneytez ME; Manzanares J; Fuentes JA
J Med Chem; 2001 Jan; 44(2):186-97. PubMed ID: 11170628
[TBL] [Abstract][Full Text] [Related]
10. Potent 4-arylalkyl-substituted 3-isothiazolol GABA(A) competitive/noncompetitive antagonists: synthesis and pharmacology.
Krehan D; Storustovu SI; Liljefors T; Ebert B; Nielsen B; Krogsgaard-Larsen P; Frølund B
J Med Chem; 2006 Feb; 49(4):1388-96. PubMed ID: 16480274
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and pharmacological evaluation of aryl aminosulfonamide derivatives as potent 5-HT(6) receptor antagonists.
Nirogi RV; Daulatabad AV; Parandhama G; Mohammad S; Sastri KR; Shinde AK; Dubey PK
Bioorg Med Chem Lett; 2010 Aug; 20(15):4440-3. PubMed ID: 20594839
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and structure-activity relationships of a new model of arylpiperazines. 8. Computational simulation of ligand-receptor interaction of 5-HT(1A)R agonists with selectivity over alpha1-adrenoceptors.
López-Rodríguez ML; Morcillo MJ; Fernández E; Benhamú B; Tejada I; Ayala D; Viso A; Campillo M; Pardo L; Delgado M; Manzanares J; Fuentes JA
J Med Chem; 2005 Apr; 48(7):2548-58. PubMed ID: 15801844
[TBL] [Abstract][Full Text] [Related]
13. Sulfonamides with the N-alkyl-N'-dialkylguanidine moiety as 5-HT7 receptor ligands.
Zajdel P; Subra G; Verdie P; Gabzdyl E; Bojarski AJ; Duszyńska B; Martinez J; Pawłowski M
Bioorg Med Chem Lett; 2009 Aug; 19(16):4827-31. PubMed ID: 19560916
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, biological evaluation, and three-dimensional in silico pharmacophore model for sigma(1) receptor ligands based on a series of substituted benzo[d]oxazol-2(3H)-one derivatives.
Zampieri D; Mamolo MG; Laurini E; Florio C; Zanette C; Fermeglia M; Posocco P; Paneni MS; Pricl S; Vio L
J Med Chem; 2009 Sep; 52(17):5380-93. PubMed ID: 19673530
[TBL] [Abstract][Full Text] [Related]
15. Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach.
Lucas S; Heim R; Negri M; Antes I; Ries C; Schewe KE; Bisi A; Gobbi S; Hartmann RW
J Med Chem; 2008 Oct; 51(19):6138-49. PubMed ID: 18763754
[TBL] [Abstract][Full Text] [Related]
16. Discovery of 5-HT6 receptor ligands based on virtual HTS.
Tasler S; Kraus J; Wuzik A; Müller O; Aschenbrenner A; Cubero E; Pascual R; Quintana-Ruiz JR; Dordal A; Mercè R; Codony X
Bioorg Med Chem Lett; 2007 Nov; 17(22):6224-9. PubMed ID: 17892934
[TBL] [Abstract][Full Text] [Related]
17. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.
Campiani G; Butini S; Fattorusso C; Catalanotti B; Gemma S; Nacci V; Morelli E; Cagnotto A; Mereghetti I; Mennini T; Carli M; Minetti P; Di Cesare MA; Mastroianni D; Scafetta N; Galletti B; Stasi MA; Castorina M; Pacifici L; Vertechy M; Di Serio S; Ghirardi O; Tinti O; Carminati P
J Med Chem; 2004 Jan; 47(1):143-57. PubMed ID: 14695828
[TBL] [Abstract][Full Text] [Related]
18. Three-dimensional models of histamine H3 receptor antagonist complexes and their pharmacophore.
Axe FU; Bembenek SD; Szalma S
J Mol Graph Model; 2006 May; 24(6):456-64. PubMed ID: 16386444
[TBL] [Abstract][Full Text] [Related]
19. Refinement of histamine H3 ligands pharmacophore model leads to a new class of potent and selective naphthalene inverse agonists.
Roche O; Nettekoven M; Vifian W; Sarmiento RM
Bioorg Med Chem Lett; 2008 Aug; 18(15):4377-9. PubMed ID: 18606542
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and characterization of the first fluorescent antagonists for human 5-HT4 receptors.
Berque-Bestel I; Soulier JL; Giner M; Rivail L; Langlois M; Sicsic S
J Med Chem; 2003 Jun; 46(13):2606-20. PubMed ID: 12801225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
